Mitsubishi Chemical Holdings (JP:4188) has released an update.
Mitsubishi Chemical Group has reported a stronger-than-expected performance for the first half of fiscal 2024, driven by increased sales in the Pharma Segment and improved market conditions in the MMA & Derivatives Segment. Despite expecting some challenges in the latter half of the fiscal year, the company has revised its full-year forecast upwards, anticipating a 16% increase in core operating income compared to previous projections.
For further insights into JP:4188 stock, check out TipRanks’ Stock Analysis page.
